home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

Highly Potent Oral Solids: Challenges and Considerations

 
  July 16, 2021  
     
 
Xtalks, Online
2021-07-20


The number and potency of highly potent drug substances are increasing. Formulators working with highly potent active pharmaceutical ingredients (APIs) are challenged to ensure the safety of personnel during development and manufacturing and healthcare workers and patients when using the final drug products. That means addressing potential issues with the homogeneity of the formulation, drug content analysis, and proper handling.

In the manufacture of highly potent compounds, special consideration needs to be given to the technical and organizational controls that will ensure operator safety and minimize cross-contamination risks. Understanding product classification and the heightened complexity of transfer and manufacturing is critical to the success of bringing these highly potent medicines to patients in need.

Register for this webinar to hear Pfizer CentreOne’s oral solids (OSD) experts discuss key consideration highly potent oral solids (HPOSD), focusing on three key challenges faced during development and manufacture. Discover more about the challenges and considerations when developing and manufacturing your HPOSD and sign up for this webcast.

 
 
Organized by: Xtalks
Invited Speakers:

Valeria Giannelli, High Active Team Manager, Pfizer Ascoli

Francesco Pastore, Plant Logistics Manager, Pfizer Ascoli

Angelo Pisetta, Process and Technical Skills Advisor, Pfizer Ascoli

Dimitris Tsimachidis, Senior Sales Manager, Pfizer CentreOne

 
Deadline for Abstracts: -
 
Registration: Register at Xtalks.
E-mail: jozeph@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.